

# Rheumatology

Common Rheumatology Labs	
<b>CRP</b>	<ul style="list-style-type: none"> <li>• Acute phase reactant, produced by liver in response to tissue injury/inflammation</li> <li>• Level rises ~ 4-6 hours after injury/infection, peak at ~24-72 hours, then falls after appropriate treatment</li> </ul>
<b>ESR</b>	<ul style="list-style-type: none"> <li>• Acute phase reactant, non-specific marker of inflammation.</li> <li>• Measures height of plasma layer vacated by RBC as cells settle in tube of anticoagulated blood in 1 hour.</li> <li>• Slower rise and slower fall compared to CRP</li> <li>• May be elevated due to anemia or hypergammaglobulinemia</li> <li>• May fall quickly in DIC or other conditions that consume or decrease production of fibrinogen</li> </ul>
<b>RF</b>	<ul style="list-style-type: none"> <li>• IgM autoantibody that reacts to Fc portion of IgG antibodies</li> <li>• Present in 5-10% of children w/ JIA; NOT useful as screening test for rheumatic disease in children</li> <li>• Useful only for predicting erosive disease in polyarticular JIA</li> <li>• Higher titers can be seen in Sjogren's Syndrome</li> <li>• Circulating immune complexes may give false positive RF results</li> </ul>
<b>ANA</b>	<ul style="list-style-type: none"> <li>• Autoantibodies directed against nuclear or perinuclear antigens.</li> <li>• Conditions associated w/ (+) ANA: <ul style="list-style-type: none"> <li>■ <b>Autoimmune</b>: autoimmune hepatitis, SLE, MCTD, JIA, PBC, UC, MG, Graves', Hashimoto's</li> <li>■ <b>ID</b>: chronic infections (malaria, SBE), RPR, viral (HIV, HSV, EBV, HCV, B19)</li> <li>■ <b>Systemic inflam.</b>: lymphoproliferative disorders, interstitial pulmonary fibrosis, asbestosis</li> </ul> </li> <li>• Medications associated w/ (+) ANA and drug-induced lupus (+anti-histone Ab): <ul style="list-style-type: none"> <li>■ Procainamide (90%)</li> <li>■ Hydralazine (65%)</li> <li>■ Anti-TNF agents (especially infliximab)</li> <li>■ INH</li> <li>■ Quinidine</li> <li>■ Phenytoin</li> <li>■ Sulfasalazine</li> <li>■ Minocycline</li> <li>■ Lithium</li> <li>■ Chlorpromazine</li> </ul> </li> <li>• Titers do not correlate w/ disease severity</li> </ul>
<b>ANCA</b>	<ul style="list-style-type: none"> <li>• Ab targeting antigens in cytoplasmic granules of neutrophils; highly sensitive for vasculitides that have predominant pulmonary and renal involvement</li> <li>• Not useful for screening patients w/ possible vasculitis due to false positive and negative results.</li> <li>• <b>Cytoplasmic (c-ANCA)</b>: antibody to proteinase-3 &amp; positive in about 90% of patients w/ Granulomatosis w/ Polyangiitis (formerly Wegener's granulomatosis)</li> <li>• <b>Perinuclear (p-ANCA)</b>: antibody to myeloperoxidase &amp; associated w/ microscopic polyangiitis, Churg-Strauss, Ulcerative colitis</li> <li>• Titers often do not correlate w/ disease severity</li> </ul>

Autoantibody Associations	
<b>ANA</b>	<ul style="list-style-type: none"> <li>• SLE</li> <li>• juvenile RA</li> <li>• dermatomyositis</li> <li>• scleroderma</li> <li>• psoriatic arthritis</li> <li>• MCTD</li> </ul>
<b>RNP</b>	<ul style="list-style-type: none"> <li>• SLE</li> <li>• overlap conditions</li> <li>• &gt; 95% of MCTD</li> </ul>
<b>Smith</b>	<ul style="list-style-type: none"> <li>• 30% of juvenile SLE, 60% of adult SLE</li> <li>• High specificity</li> <li>• Remains positive when SLE in remission</li> </ul>
<b>dsDNA</b>	<ul style="list-style-type: none"> <li>• 70-80% of SLE</li> <li>• High specificity</li> <li>• Associated w/ SLE activity and lupus nephritis</li> </ul>
<b>Scl-70</b>	<ul style="list-style-type: none"> <li>• 30% of diffuse scleroderma</li> <li>• 15% of limited scleroderma</li> <li>• Assoc. w/ pulmonary fibrosis</li> </ul>